Biotechnology New Standard Of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy – Icecure Medical (NASDAQ:ICCM) Read more
Biotechnology Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa’s Steroid For Post-Eye Surgery Pain, Inflammation – Eyenovia (NASDAQ:EYEN) Read more
Biotechnology Merck’s Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows – Merck & Co (NYSE:MRK) Read more